Board of Directors
Charles Ardai is the chairman of Schrödinger, Inc. He also serves as a managing director in the D. E. Shaw group, a specialized investment and technology development firm whose activities center on various aspects of the intersection between technology and finance. Prior to joining Schrödinger, he served as president and chief executive officer of Juno Online Services, Inc., a publicly traded technology firm he founded in 1995. He graduated summa cum laude from Columbia University in 1991.
Ramy Farid, President and CEO, and member of the Board of Directors, joined Schrödinger in 2002. Dr. Farid also serves on the Boards of Nimbus Therapeutics, a biotech company he helped found with Atlas Ventures, and Morphic Therapeutic, another biotech company co-founded by Schrödinger. Prior to joining Schrödinger, Dr. Farid was an Assistant Professor in the Chemistry Department at Rutgers University. He was an NIH Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania and received his Ph.D. in Chemistry from Caltech.
Richard A. Friesner is Professor of Chemistry at Columbia University and Director of the Columbia Center for Biomolecular Simulation. He is a member of the National Academy of Sciences and American Academy of Arts of Sciences, and has been awarded a Sloan Foundation Fellowship, Camille and Henry Dreyfus Teacher-Scholar Award, and an NIH Research Career Development Award. Current interests include quantum chemistry, development of potential functions for molecular simulation, continuum electrostatic models, and protein folding. Dr. Friesner is a co-founder of Schrödinger, and a member of Schrödinger's Board of Directors.
Timothy M. Wright is Executive Vice-President, Translational Sciences at the California Institutes for Biomedical Research (Calibr), a not-for-profit drug discovery institute in La Jolla, CA. He is a physician-scientist trained at the University of Delaware (BA, Biology) and the Johns Hopkins University School of Medicine (MD, Post-doctoral training). His academic career extended from Johns Hopkins to the University of Pittsburgh (Chief of Rheumatology and Clinical Immunology, endowed Professorship in Medicine) until 2001, when he moved to industry – first to Pfizer (2001- 2004) and then to Novartis (2004-2015). He served in leadership roles spanning early discovery to late stage development – most recently the Global Head of Development for Novartis Pharma. He also serves as a scientific advisor to the Bill and Melinda Gates Foundation.